Revenue
2020
2021
2022
2023
2024
2025
Zymeworks Inc. (ZYME)
Price—Loading quote
Net income
2020
2021
2022
2023
2024
2025
Free cash flow
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Revenue | $106.0M | $76.3M | $76.0M | $412.5M | $26.7M | $39.0M |
| Research & development | $137.0M | $134.6M | $143.6M | $208.6M | $199.8M | $171.2M |
| Operating income | −$92.5M | −$137.1M | −$138.1M | $130.5M | −$215.6M | −$187.5M |
| EBITDAderived | −$84.8M | −$128.4M | −$127.9M | $137.8M | −$209.1M | −$180.0M |
| Net income | −$81.1M | −$122.7M | −$118.7M | $124.3M | −$211.8M | −$180.6M |
| Basic EPSper diluted share | -$1.08 | -$1.62 | -$1.72 | $1.91 | -$4.11 | -$3.58 |
| Diluted EPSper diluted share | -$1.08 | -$1.62 | -$1.72 | $1.90 | -$4.61 | -$3.58 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jan 12, 2026Form 4 | Hollywood MarkEVP & Chief Operating Officer | SellCommon Stock | 6.1K | $22.67 | $138.7K | 132.9K |
| Jan 12, 2026Form 4 | Smith Jeffrey T LEVP & Chief Medical Officer | SellCommon Stock | 9.3K | $22.67 | $211.1K | 26.7K |
| Jan 12, 2026Form 4 | Moore Paul AndrewChief Scientific Officer | SellCommon Stock | 9.6K | $22.67 | $216.7K | 48.5K |
| Jan 12, 2026Form 4 | Galbraith KennethChair & CEO | SellCommon Stock | 30.4K | $22.67 | $689.7K | 226.8K |
| Jan 5, 2026Form 4 | Smith Jeffrey T LEVP & Chief Medical Officer | SellCommon Stock | 10.5K | $25.10 | $264.5K | 18.4K |